Results 181 to 190 of about 119,934 (290)

Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate‐to‐Severe Atopic Dermatitis

open access: yesAllergy, EarlyView.
Data were included from adolescents with moderate‐to‐severe AD treated with the JAK1 inhibitor abrocitinib (200 mg/100 mg) across JADE clinical trials. Improvements in skin clearance (per EASI‐75) and itch (per PP‐NRS4) were maintained for up to 112 weeks with both abrocitinib doses.
Amy S. Paller   +13 more
wiley   +1 more source

Non‐Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First‐In‐Class IgE Antibody Recognising Folate Receptor Alpha

open access: yesAllergy, EarlyView.
MOv18 IgE, the first‐in‐class IgE antibody targeting the cancer antigen folate receptor alpha (FR⍺) showed early signs of efficacy and was well tolerated in a first‐in‐human clinical trial, with transient urticarial skin reactions as the most common toxicity.
Chara Stavraka   +28 more
wiley   +1 more source

A Study on Scratching Behavior Characteristics in Patients With Various Types of Chronic Pruritus. [PDF]

open access: yesAllergy Asthma Immunol Res
Lee JH   +11 more
europepmc   +1 more source

Direct Single‐Dose Drug‐Provocation Test Is Safe for Delabelling Penicillin Low‐Risk Reactions in Adults

open access: yesAllergy, EarlyView.
We show that direct single‐dose provocation test was both safe and effective in delabeling penicillin allergy in low‐risk adult patients, including those with mild delayed skin reactions and those with unknown reactions, such as childhood labels and past syncope episodes. In those who react in the drug provocation test, a T‐cell mechanism was confirmed
Marina Labella   +7 more
wiley   +1 more source

Comparison of itch characteristics and sleep in patients with brachioradial pruritus and notalgia paresthetica: A retrospective analysis from 2 itch centers

open access: yesJAAD International, 2021
Zoe M. Lipman, BS   +5 more
doaj  

Home - About - Disclaimer - Privacy